PEAK6 Investments’s BridgeBio Pharma BBIO Stock Holding History

PEAK6 Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,500	Closed	-$190K	–	3478
2024 Q2	$190K	Buy	7,500 +6,500	+650%	+$178K	﹤0.01%	2781
2024 Q1	$30.9K	Sell	1,000 -6,500	-87%	-$221K	﹤0.01%	3647
2023 Q4	$303K	Buy	7,500 +2,000	+36%	+$60.1K	﹤0.01%	2958
2023 Q3	$145K	Buy	+5,500	New	+$156K	﹤0.01%	3232

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Investments's BBIO Position: Q3 2024 in Review

PEAK6 Investments sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 19,082 shares — an estimated $501K sold.

PEAK6 Investments first reported a position in BBIO in Q2 2022 and held it in 6 quarters. The position peaked at $740K in Q1 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

PEAK6 Investments reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
PEAK6 Investments sold 19,082 BridgeBio Pharma shares in Q3 2024, an estimated $501K.
PEAK6 Investments first reported a position in BridgeBio Pharma in Q2 2022 and held it in 6 quarters.
PEAK6 Investments's BridgeBio Pharma position peaked at $740K in Q1 2024.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.